What are the indications, recommended protocol, and patient preparation for a multiparametric prostate MRI?

Multiparametric Prostate MRI: Indications, Protocol, and Patient Preparation

Multiparametric MRI (mpMRI) of the prostate should be performed prior to biopsy in biopsy-naïve patients at elevated risk of clinically significant prostate cancer (csPCa) and in patients with prior negative TRUS biopsy who remain at high risk, using a standardized PI-RADS compliant protocol. 1, 2

Primary Indications

Biopsy-Naïve Patients

• Perform mpMRI before biopsy in patients at elevated risk of csPCa who are candidates for curative management 1, 2
• If mpMRI is positive (PI-RADS 3-5): perform both MRI-targeted biopsy AND systematic TRUS biopsy together to maximize detection 3, 2
• If mpMRI is negative (PI-RADS 1-2): consider forgoing biopsy after shared decision-making, particularly in lower-risk patients 3, 2

Prior Negative Biopsy

• Strongly indicated for patients with prior negative TRUS biopsy and persistently elevated PSA or continued clinical concern 1
• If positive: perform targeted biopsy (consider adding systematic biopsy based on risk profile and time since prior biopsy) 2
• If negative: consider forgoing repeat biopsy after discussion with patient 2

Staging

• Appropriate for intermediate and high-risk disease to evaluate extracapsular extension and seminal vesicle invasion 1
• High-risk criteria include: PSA ≥20 ng/mL, Gleason score ≥8, clinical stage ≥T3, or any two of: stage T2b-c, Gleason 7, PSA 10-20 ng/mL 1

Active Surveillance

• Useful for re-evaluation of tumor grade and monitoring disease progression 1

Recommended Protocol (PI-RADS v2.1 Compliant)

All mpMRI examinations must include these core sequences 3, 2, 4:

Essential Sequences

1. T2-weighted imaging (T2WI): High-resolution anatomic imaging

   • Primary determinant for transitional zone lesions 5

2. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps

   • Primary determinant for peripheral zone lesions 5
   • Considered a "game changer" in prostate cancer detection 1

3. Dynamic contrast-enhanced MRI (DCE-MRI)

   • Provides secondary classification 5
   • Note: The incremental benefit of DCE is modest 1; biparametric MRI (omitting DCE) is emerging as an alternative 6, though full mpMRI remains standard

Technical Requirements

• Field strength: 1.5T or 3T (3T preferred when available) 7
• Endorectal coil: Optional; not mandatory with modern 3T systems 7, 8
• PI-RADS compliance: All imaging and interpretation must follow current PI-RADS guidelines 2, 4

Patient Preparation

Pre-Examination Requirements 9, 7

Essential anamnestic data to collect:

• PSA levels and trends
• Prior biopsy results (if applicable)
• Gleason score (if known)
• Clinical stage
• Family history of prostate cancer
• Current medications (particularly anticoagulants)
• Prior prostate procedures or treatments

Preparation steps:

• Bowel preparation: Consider rectal enema or suppository to reduce rectal gas and stool artifacts 9, 7
• Bladder: Moderately full bladder (not empty, not overdistended) 7
• Timing: If post-biopsy, wait 6-8 weeks to allow hemorrhage resolution 7
• Contrast screening: Standard MRI safety screening for gadolinium administration 9

Critical Interpretation Considerations

PI-RADS Scoring System 3, 5

• PI-RADS 1-2: Low likelihood of csPCa; consider no biopsy in appropriate clinical context
• PI-RADS 3: Equivocal; use PSA density (PSAD) to guide decision (threshold 0.1-0.15 ng/mL²) 3
• PI-RADS 4-5: High likelihood of csPCa; proceed with targeted biopsy

Performance Characteristics

• Sensitivity: 57-79% for extracapsular extension (reader-dependent) 1, 10
• Specificity: 91-96% for local staging 1
• Reader experience matters significantly: Expert reading substantially improves accuracy, particularly in younger patients 10

Common Pitfalls and Caveats

1. Reader variability: Interobserver agreement is moderate (kappa 0.41-0.67) 3, 10; consider double reading by experienced radiologists for optimal accuracy 10

2. PI-RADS 3 lesions: These have insufficient positive rates for csPCa 6; use PSAD and clinical risk factors to guide biopsy decisions 3

3. Negative mpMRI does not exclude cancer: Sensitivity is imperfect; approximately 10-20% of csPCa may be missed 1, 10

4. Post-biopsy hemorrhage: Can obscure lesions; adequate waiting period essential 7

5. Systematic biopsy still needed: Even with positive mpMRI, combining targeted AND systematic biopsies maximizes csPCa detection 3, 2

6. Quality standards: Examination must meet validated technical standards and PI-RADS specifications 9, 4